Conference Coverage

PSYCHIATRY UPDATE 2016


 

Management of PTSD
Carol S. North, MD, MPE, DFAPA, University of Texas Southwestern Medical Center

The pathology of PTSD is thought to be related to abnormal neurobiological processing of acquired fear responses. Psychotherapy and pharmacotherapy have demonstrated effectiveness in PTSD, but it is unclear if either modality alone or combined is better; treatment choice should be guided by patient preference. Sertraline and paroxetine have FDA indications for PTSD, but all selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are considered first-line agents. Prazosin is effective for nightmares and sleep disturbances. Sedative-hypnotics and benzodiazepines can relieve specific symptoms, such as anxiety or insomnia, but do not address all PTSD symptomatology. Cognitive processing therapy and prolonged exposure therapy have the best evidence of efficacy.

Pages

Recommended Reading

FDA announces new plan to combat opioid abuse
MDedge Psychiatry
NIDA releases strategic plan to prevent, treat substance use disorders
MDedge Psychiatry
ThriveNYC could help treat and destigmatize mental, behavioral disorders
MDedge Psychiatry
Designer drug symptoms can mimic schizophrenia, anxiety, depression
MDedge Psychiatry
Opioid prescribing: An odyssey of challenges
MDedge Psychiatry
Opiate drug detox appears safe in pregnancy
MDedge Psychiatry
Pot tied to increased risk of substance use disorders, not depression or anxiety
MDedge Psychiatry
We are not ‘psychiatrists’; 'The beauty of the asylum’; Challenges with false-positive urine drug screens
MDedge Psychiatry
Marijuana tourists also visiting Colorado EDs
MDedge Psychiatry
VIDEO: How proposed patient substance use privacy rule impacts physicians
MDedge Psychiatry